My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

uniQure N.V. - Ordinary Shares (NQ:QURE)

30.33 +0.45 (+1.51%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

3 Micro-Cap Stocks That Could Be Moonshots ↗

November 14, 2023

If you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields.

Via InvestorPlace

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 07, 2023

From uniQure Inc.

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

November 02, 2023

Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning!

Via InvestorPlace

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

October 24, 2023

From uniQure Inc.

Via GlobeNewswire

Why Shares of uniQure Are Up Thursday ↗

October 05, 2023

The company announced a reorganization that included layoffs.

Via The Motley Fool

Why Shares of uniQure Are Dropping Tuesday ↗

September 05, 2023

The company is facing being delisted from the S&P 600 Index.

Via The Motley Fool

Topics Stocks

Gene Therapy Player UniQure To Lay Off 20% Of Workforce, Stop Parkinson's Study ↗

October 05, 2023

uniQure N.V. (NASDAQ: QURE) announced to cut about 20% of its total workforce, or about 114 jobs, and end investments in more than half of its research and technology

Via Benzinga

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

October 05, 2023

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 02, 2023

From uniQure Inc.

Via GlobeNewswire

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗

September 15, 2023

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

Via Investor's Business Daily

Analyst Expectations for uniQure's Future ↗

August 02, 2023

Via Benzinga

Why uniQure Stock Cratered This Week ↗

June 22, 2023

An interim analysis for the company's Huntington's disease gene therapy wasn't a hit with investors.

Via The Motley Fool

Chardan Capital Maintains Buy Rating for uniQure: Here's What You Need To Know ↗

June 22, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

October 02, 2023

On Monday, 369 companies set new 52-week lows.

Via Benzinga

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

September 05, 2023

Clinical trial initiation expected in the fourth quarter of 2023

From uniQure Inc.

Via GlobeNewswire

Why UniQure Stock Is Trading Down Today ↗

June 21, 2023

UniQure N.V. (NASDAQ: QURE) shares are lower after the company announced interim data from the Phase I/II trial of AMT-130 in Huntington's Disease.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

September 19, 2023

During Tuesday's session, 275 companies made new 52-week lows.

Via Benzinga

Airbnb, Blackstone Rise On News They'll Join S&P 500 Index ↗

September 02, 2023

ABNB and BX will join Sept. 18 as part of a quarterly rebalancing.

Via Investor's Business Daily

Topics Stocks

Why America's Car-Mart Are Trading Lower By 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 05, 2023

Gainers Verb Technology Company, Inc. (NASDAQ: VERB) shares jumped 164% to $1.89 after the completed and launched a technology integration and strategic relationship with global social media platform...

Via Benzinga

3 Tantalizing Stocks to Buy for Under $10 ↗

August 26, 2023

While investors should stick with the predictable ideas, those that want robust returns should target these stocks under $10 to buy.

Via InvestorPlace

uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

August 01, 2023

From uniQure Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Thursday ↗

July 27, 2023

During Thursday, 56 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

July 25, 2023

On Tuesday, 56 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

July 26, 2023

Wednesday saw 59 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 21, 2023

On Friday, 54 companies hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

July 24, 2023

On Monday morning, 70 companies achieved new lows for the year.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

July 20, 2023

During Thursday's session, 40 stocks hit new 52-week lows.

Via Benzinga

uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

June 26, 2023

~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bring extensive track record in leading drug development and execution ~

From uniQure Inc.

Via GlobeNewswire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm

June 22, 2023

From The Schall Law Firm

Via Business Wire

Nordson To Rally Over 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗

June 22, 2023

Chardan Capital cut the price target for uniQure N.V. (NASDAQ: QURE) from $45 to $27. Chardan Capital analyst Matthew Barcus maintained a Buy rating. uniQure shares fell 1.5% to $11.45 in pre-market...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.